Trevi Therapeutics/TRVI

$2.92

-2.01%
-
1D1W1MYTD1YMAX

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Ticker

TRVI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jennifer Good

Employees

25

Headquarters

New haven, United States

Website

-

TRVI Metrics

BasicAdvanced
$205.5M
Market cap
-
P/E ratio
-$0.29
EPS
0.89
Beta
-
Dividend rate
$205.5M
0.88939
$4.00
$0.97
300.11K
15.032
0.038
0.185
-27.37%
-30.59%
-30.09%
2.465
2.49
54.57%

What the Analysts think about TRVI

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
151.03% upside
High $9.00
Low $6.00
$2.92
Current price
$7.33
Average price target

TRVI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-7.8M
2.63%
Profit margin
0%
-

TRVI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.73%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.06
-$0.07
-$0.08
-$0.08
-
Expected
-$0.07
-$0.09
-$0.09
-$0.09
-$0.09
Surprise
-18.18%
-17.65%
-12.73%
-12.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Trevi Therapeutics stock?

Trevi Therapeutics (TRVI) has a market cap of $205.5M as of April 14, 2024.

What is the P/E ratio for Trevi Therapeutics stock?

The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of April 14, 2024.

Does Trevi Therapeutics stock pay dividends?

No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Trevi Therapeutics dividend payment date?

Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.

What is the beta indicator for Trevi Therapeutics?

Trevi Therapeutics (TRVI) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Trevi Therapeutics stock price target?

The target price for Trevi Therapeutics (TRVI) stock is $7.33, which is 151.03% above the current price of $2.92. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Trevi Therapeutics stock

Buy or sell Trevi Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing